Log In

 

Company Name : Boehringer Ingelheim

Tuesday, November 7, 2017 10:55AM IST (5:25AM GMT)

(BW)(BOEHRINGER-INGELHEIM)

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®


48-week Phase III data showed Cyltezo® and Humira® have similar efficacy, safety and immunogenicity in people with rheumatoid arthritis1; Patients who switched at week 24 from Humira® to Cyltezo® showed no difference to continuous Humira® usage1; Data will be presented at the American College of Rheumatology / Association of Rheumatology Health Professionals Annual Meeting


Ingelheim, Germany

Boehringer Ingelheim announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira®*. The 48-week data showed that Cyltezo® is equivalent, with no clinically meaningful differences in efficacy, safety and immunogenicity to Humira® in people with moderately-to-severely active rheumatoid arthritis (RA), including in patients who switched from Humira® to Cyltezo® at week 24.1

 

“These data are an important addition to the robust body of evidence demonstrating Cyltezo® is biosimilar to Humira®,” said Karsten Kissel, MD, Head of Global Medical Affairs Biosimilars at Boehringer Ingelheim. “Biosimilars have potential cost benefits to the healthcare system and support affordable access to important biologic medicines for patients living with chronic inflammatory diseases like RA.”

 

“In addition to the 48-week efficacy results, the adalimumab biosimilar Cyltezo® showed equivalent safety and immunogenicity to Humira®,” said Stanley B. Cohen, MD, Metroplex Clinical Research Center, Presbyterian Hospital, Dallas, Texas. “Consistent results were also demonstrated when patients were switched to Cyltezo® from the reference product.”

 

These data will be presented at the American College of Rheumatology / Association of Rheumatology Health Professionals Annual Meeting in San Diego, California.

 

In the EU, Cyltezo® recently received positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for multiple chronic inflammatory diseases including, in adults:

 
  • Moderate to severely active rheumatoid arthritis
  • Psoriatic arthritis
  • Moderate to severely active Crohn's disease
  • Severe active ankylosing spondylitis
  • Moderate to severely active ulcerative colitis
  • Severe axial spondyloarthritis without radiographic evidence of AS
  • Moderate to severe chronic plaque psoriasis
  • Moderate to severe hidradenitis suppurativa
  • Non-infectious intermediate, posterior and panuveitis.

The CHMP also recommended approval of Cyltezo® for the treatment of paediatric inflammatory diseases, including moderate to severe Crohn's disease (age six and older), severe chronic plaque psoriasis (age four and older), enthesitis-related arthritis (age six and older) and polyarticular juvenile idiopathic arthritis (age two and older).

 

Cyltezo® is not commercially available in Europe or the U.S. at this time. In any event Boehringer Ingelheim does not intend to launch Cyltezo® in the EU before expiration of the respective SPC for adalimumab in October 2018. Boehringer Ingelheim is currently engaged in patent litigation with AbbVie in the U.S.

 

Intended audiences:

 

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

 

For references and notes to editors, please visit : http://www.boehringer-ingelheim.com/press-release/one-year-data-showing-cyltezo-equivalent-humira

 

 

 

 


Click here for Media Contact Details
CONTACTS :

Media Contact
Boehringer Ingelheim
Corporate Communications
Media + PR
Dr. Julia Knebel
Phone: +49 6132 – 77 95614
Fax: +49 6132 – 77 6601
Email: press@boehringer-ingelheim.com
www.boehringer-ingelheim.com


More News from Boehringer Ingelheim

18/02/2018 1:59PM

Systemic Sclerosis World Congress: Inspirational Patient Stories Reveal the Challenging Realities of Living with Devastating Rare Disease

'More Than Scleroderma: The Inside Story' provides real-life stories and education about the life-threatening disease New and truly inspiring patient stories are revealed Help raise awareness of this ...

04/01/2018 6:21PM

Boehringer Ingelheim Demonstrates Continuous Commitment to Its Venture Fund and Fostering Innovation by More than Doubling Funding to 250 M€

Boehringer Ingelheim announced an increase in funding for its corporate venture fund, known as the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million. The additional funds will be used to invest in ...

11/12/2017 7:30PM

Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research Partnerships in 2017

2017 marks a year of significant advancement for Boehringer Ingelheim as it secured a range of external partnerships with the goal of transforming the lives of patients and winning the fight against cancer. External ...

Similar News

20/02/2018 1:15PM

Herbalife Nutrition India Launches Strawberry Flavour of Dinoshake Nutritional Children's Drink Mix

Herbalife Nutrition, a global nutritional company, announced it is doubling the tastes available for Dinoshake Nutritional Children’s Drink Mix in Indai, adding Strawberry flavour to accompany the delicious Dinoshake ...

No Image

20/02/2018 1:06PM

बेस्ट क्योर फाउंडेशन (बीसीएफ) और टीमबेस्ट कंपनीज अंतरराष्ट्रीय स्तर पर मुनाफा न कमाने वाली/गैरसरकारी बेस्ट क्योर हेल्थ सिस्टम और बेस्ट क्योर इंश्योरेंस की शुरुआत कर रहे हैं ताकि 10 ट्रिलियन अमेरिकी डॉलर से ज्यादा की अंतरराष्ट्रीय हेल्थकेयर डिलीवरी सिस्टम को बहुत बेहतर और कम महंगा बनाया जा सके

कृष्णन सुथांथिरण ने 2007 में बेस्ट केयर फाउंडेशन (मुनाफ न कमाने वाले एक गैरसरकारी संगठन) की स्थापना की ताकि उच्च गुणवत्ता वाले हेल्थकेयर और उच्च शिक्षा को किफायती बनाया जा सके और अंतरराष्ट्रीय स्तर पर हर ...